A phase I study of reldesemtiv in healthy volunteers to assess higher doses
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2019
Price : $35 *
At a glance
- Drugs Reldesemtiv (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions
- 08 Aug 2019 According to a Cytokinetics media release, the company is evaluating the data from the study to inform the design of potential future clinical trials.
- 08 Aug 2019 Status changed from planning to completed, according to a Cytokinetics media release.
- 22 Jan 2019 According to a Cytokinetics media release, the company expects to initiate this study in the first quarter of 2019.